Research programme: proto oncogene protein B-raf inhibitors - GlaxoSmithKline

Drug Profile

Research programme: proto oncogene protein B-raf inhibitors - GlaxoSmithKline

Alternative Names: SB-590885

Latest Information Update: 18 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Imidazoles; Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 07 May 2005 Preclinical trials in Solid tumours in United Kingdom (unspecified route)
  • 07 May 2005 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top